TABLE 1.
Deficiency complementation tests
| Deficiency breakpoints | Mean aggression score (SE)
|
ANOVA P-values
|
||||
|---|---|---|---|---|---|---|
| Deficiency genotype | Df/88 MAS | Df/Ore MAS | Line (L) | Genotype (G) | L × G | |
| w1118; Df(3L)ED4341/TM6C, Sb1 | 63F6;64B11 | 12.1 (1.12) | 12.0 (1.21) | 0.9820 | 0.0082 | 0.9224 |
| w1118; Df(3L)ED4342/TM6C, Sb1 | 64B1;64B13 | 15.6 (1.54) | 16.1 (1.89) | 0.8175 | 0.8947 | 0.9054 |
| w1118; Df(3L)ED210/TM6C, Sb1 | 64B11;64D1 | 22.0 (1.75) | 18.3 (1.86) | 0.2237 | 0.0026 | 0.1850 |
| w1118; Df(3L)Exel6105/TM6B, Tb1 | 64D1;64D6 | 16.9 (0.98) | 19.9 (0.66) | 0.0499 | 0.0103 | 0.4879 |
| w1118; Df(3L)Exel6106/TM6B, Tb1 | 64D6;64E2 | 22.8 (1.04) | 22.5 (1.83) | 0.6360 | <0.0001 | 0.4709 |
| w1118; Df(3L)Exel6107/TM6B, Tb1 | 64E5;64F5 | 30.3 (2.30) | 21.8 (1.87) | 0.0089 | <0.0001 | 0.0003* |
| w1118; Df(3L)Exel7210/TM6B, Tb1 | 65A1;65A5 | 17.5 (0.98) | 20.2 (2.23) | 0.0997 | 0.0080 | 0.6151 |
| w1118; Df(3L)Exel8101/TM6B, Tb1 | 65A3;65A9 | 21.1 (1.84) | 18.5 (1.46) | 0.6404 | 0.0007 | 0.1048 |
| w1118; Df(3L)ED211/TM6C, Sb1 | 65A9;65B4 | 11.9 (1.57) | 11.3 (0.94) | 0.8709 | 0.0036 | 0.7789 |
| w1118; Df(3L)ED212/TM6C, Sb1 | 65A9;65D5 | 21.4 (2.77) | 18.8 (1.05) | 0.4203 | 0.0043 | 0.3622 |
| w1118; Df(3L)Exel6110/TM6B, Tb1 | 65E4;65E8 | 16.5 (1.15) | 17.0 (1.11) | 0.4007 | 0.2697 | 0.6828 |
| w1118; Df(3L)Exel6111/TM6B, Tb1 | 65E7;65F4 | 24.3 (1.24) | 16.9 (1.02) | 0.0114 | <0.0001 | 0.0002* |
| w1118; Df(3L)Exel8104/TM6B, Tb1 | 65F7;66A4 | 19.3 (1.63) | 15.7 (1.16) | 0.4032 | 0.1167 | 0.0519 |
| w1118; Df(3L)ED4408/TM6C, Sb1 | 66A22;66C5 | 12.8 (1.32) | 10.2 (1.44) | 0.3737 | 0.0032 | 0.3146 |
| w1118; Df(3R)Exel7317/TM6B, Tb1 | 66C5;66D3 | 17.8 (0.88) | 16.2 (1.12) | 0.9453 | 0.1820 | 0.1838 |
| w1118; Df(3L)ED4421/TM6C, Sb1 | 66D14;67B1 | 11.9 (1.89) | 8.8 (1.89) | 0.3173 | 0.0005 | 0.2679 |
| w1118; Df(3L)Exel6114/TM6B, Tb1 | 67B10;67C5 | 18.5 (1.21) | 15.3 (0.87) | 0.4438 | 0.2143 | 0.0450 |
| w1118; Df(3L)Exel9048/TM6B, Tb1 | 67D1;67D2 | 32.2 (1.33) | 18.1 (1.27) | <0.0001 | <0.0001 | <0.0001* |
| w1118; Df(3L)ED4470/TM6C, Sb1 | 68A6;68E1 | 14.0 (1.86) | 11.6 (2.20) | 0.4551 | 0.0590 | 0.3935 |
| w1118; Df(3L)ED4483/TM6C, Sb1 | 69A4;69D3 | 17.7 (1.17) | 17.0 (2.03) | 0.8489 | 0.2353 | 0.7615 |
| w1118; Df(3L)ED215/TM6C, Sb1 | 69B5;69C4 | 16.9 (1.93) | 10.9 (0.72) | 0.0372 | 0.2946 | 0.0282 |
| w1118; Df(3L)ED4486/TM6C, Sb1 | 69C4;69F6 | 23.9 (2.16) | 14.3 (1.59) | 0.0018 | 0.0212 | 0.0013* |
| w1118; Df(3L)Exel6261/TM6B, Tb1 | 69F6;70A3 | 18.5 (1.44) | 15.8 (1.09) | 0.5931 | 0.1556 | 0.0805 |
| w1118; Df(3L)ED4502/TM6C, Sb1 | 70A3;70C10 | 14.9 (1.08) | 20.3 (1.45) | 0.0424 | 0.1539 | 0.0554 |
| w1118; Df(3L)ED4543/TM6C, Sb1 | 70C6;70F4 | 14.6 (2.34) | 11.9 (1.18) | 0.3929 | 0.1078 | 0.3366 |
| w1118; Df(3L)ED217/TM6C, Sb1 | 70F4;71E1 | 20.0 (1.75) | 17.8 (1.43) | 0.4725 | 0.0267 | 0.4068 |
| w1118; Df(3L)ED218/TM6C, Sb1 | 71B1;71E1 | 17.6 (0.90) | 15.6 (0.91) | 0.4800 | 0.4708 | 0.4072 |
| w1118 (Exel control) | N/A | 14.8 (0.67) | 16.2 (0.96) | N/A | N/A | N/A |
| w1118 (ED control) | N/A | 15.6 (0.80) | 15.7 (1.16) | N/A | N/A | N/A |
Deficiency stocks used in quantitative complementation tests. ED denotes DrosDel deficiencies and Exel indicates Exelixis deficiencies. The isogenic background stocks for both sets of deficiencies are listed as controls. Boldface type indicates deficiencies that failed to complement the QTL for aggressive behavior (P-values of the L × G term from ANOVA < 0.05). *Significant following a Bonferroni correction for multiple tests. Df(3L)ED4502 (results in italics) was marginally significant and was therefore included in complementation tests to mutations.